Actavis snaps up Durata, newly approved antibiotic in $675M buyout

John Carroll Buyout-hungry Actavis–which is alternatively spotlighted as both a buyer and a possible buyout target–has snapped up Chicago-based Durata Therapeutics and its ...

NIH sickle cell partner AesRx moves up the food chain in Baxter buyout

John Carroll Having played a pioneering role collaborating with the NIH on a new drug for sickle cell disease, Newton, MA-based AesRx has moved up the food chain after completing a ...

Nicox adds to eye-drug pipeline with $120M buyout deal for Aciex

John Carroll In a deal designed to beef up its pipeline of ophthalmology drugs, France's Nicox has snapped up Boston-based Aciex for $ 65 million in newly issued shares and up ...

Forest CEO Saunders to lead combined company after Actavis buyout

Alok Saboo FierceBiotech News

Forest lands Furiex and expands GI business in $1.5B buyout deal

John Carroll Furiex has landed its big buyout deal. After nabbing promising late-stage data on a new drug for irritable bowel syndrome and virtually slapping a "for sale" ...

Buyout buzz: Allergan made a pass at Shire before Valeant came calling

Damian Garde Before it started getting unwanted attention from the takeout artists at Valeant, Allergan made buyout overtures of its own to Shire, Reuters reports, getting little interest ...

Medigene gambles on dendritic cell cancer vaccines in Trianta buyout

John Carroll Germany's Medigene AG has nabbed a small cancer vaccine developer in a buyout which will add a team of investigators from one of the country's top research institutes. ...

NuPathe nixes Endo’s buyout offer to hook up with Teva

Tracy Staton FiercePharma News

Ikaria takes a $1.6B buyout but spins out some early-stage programs

Damian Garde Rumored takeover target Ikaria has signed a deal to sell the majority of its business to a private equity outfit for about $ 1.6 billion, spinning out a new company to ...

Amgen earnings jump amid Onyx buyout, Asia deal

Eric Palmer With the ink on its $ 10.4 billion deal for Onyx Pharmaceuticals not yet dry, it might have been exepcted to be the only thing Amgen would key on in its third-quarter ...

M&A buzz: ViroPharma could go for $60 per share in buyout

Ryan McBride The rare-disease drug specialist ViroPharma has been generating buyout buzz all week after reports that the company brought on the services of Goldman Sachs to hunt for ...

Roche chief tamps down talk of $13.5B BioMarin buyout

Tracy Staton Roche CEO Severin Schwan put the kibosh on chatter about its supposed plans to raise funding for a BioMarin Pharmaceutical buyout. According to Dealreporter, the Swiss ...
Page 3 of 712345...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS